Skip to main content
SpringerLink
Log in

A Risk-Benefit Assessment of Serotonin 5-HT3 Receptor Antagonists in Antineoplastic Therapy-Induced Emesis

  • Review Article
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Insight into the pathophysiology of antineoplastic therapy-induced nausea and vomiting led to the development of the serotonin 5-HT3 receptor antagonists as the most potent class of antiemetic agents. Among those which have been investigated are ondansetron, granisetron, tropisetron and dolasetron. A riskbenefit analysis of these drugs must not only account for the modest clinical differences in efficacy and tolerability, but also should include such issues as ease of use, route of administration, dosage considerations and patient preference.

Pharmacokinetic and preclinical studies reveal distinctions among these antiemetics, but, overall, these distinctions do not translate in to clinically significant differences. In clinical trials, the most widely studied members of the 5-HT3 receptor antagonists are granisetron and ondansetron, which have been found to possess equivalent antiemetic efficacy. Dolasetron and tropisetron are also available, and some randomised trials have also documented their similar antiemetic activity, depending on the doses and schedules used. The equivalent efficacy of oral granisetron 2mg versus intravenous ondansetron 32mg has recently been demonstrated in prospective randomised clinical trials in patients receiving either highly emetogenic or moderately emetogenic antineoplastic therapy. The utilisation and efficacy of oral ondansetron and dolasetron in patients receiving moderately emetogenic antineoplastic therapy has also been documented.

This review offers a brief overview of the pharmacokinetic and preclinical research on the 5-HT3 antagonists, a review of the comparative clinical trials of the major members of this class and a summary risk-benefit assessment that considers clinical applicability and cost, as well as efficacy and safety.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Perez EA, Gandara DR. Advances in the control of chemotherapy-induced emesis. Ann Oncol 1992; 3 Suppl. 3: S47–50

    Article  Google Scholar 

  2. Del Favero A, Roila F, Tonato M. Reducing chemotherapy-induced nausea and vomiting: current perspectives and future possibilities. Drug Saf 1993; 9(6): 410–28

    Article  PubMed  Google Scholar 

  3. Aapro MS. Controlling emesis related to cancer therapy. Eur J Cancer 1991; 27(3): 356–61

    Article  PubMed  CAS  Google Scholar 

  4. Fozard JR. MDL 72222: a potent and highly selective antagonist of neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1984; 326: 36

    Article  PubMed  CAS  Google Scholar 

  5. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986; 88: 497–9

    Article  PubMed  CAS  Google Scholar 

  6. Miner WD, Sanger GJ, Turner DH. Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiationevoked emesis. Eur J Cancer 1987; 56: 159–62

    CAS  Google Scholar 

  7. Miner WD, Sanger GJ, Turner DH. Comparison of the effect of BRL 24924, metoclopramide and domperidone on cis-platininduced emesis in the ferret. Br J Pharmacol Proc 1986; Suppl. 88: 374P

    Google Scholar 

  8. Aapro MS. 5-HT3 receptor antagonists: An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991; 42(4): 551–68

    Article  PubMed  CAS  Google Scholar 

  9. Blower PR. Comparative pharmacology of 5-HT3 receptor antagonists. Hosp Formul 1994; 29 Suppl. 5: S4–9

    Google Scholar 

  10. Schworer H, Racke K, Kilbinger H. Cisplatin increases the release of 5-hydroxytryptamine (5-HT) from the isolated vascularly perfused small intestine of the guinea-pig: Involvement of 5-HT3 receptors. Naunyn Schmiedebergs Arch Pharmacol 1991; 344: 143–49

    Article  PubMed  CAS  Google Scholar 

  11. Gebauer A, Merger M, Kilbinger H. Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea pig small intestine. Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 137–40

    Article  PubMed  CAS  Google Scholar 

  12. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995; 13(4): 1036–43

    PubMed  CAS  Google Scholar 

  13. Kytril (granisetron hydrochloride injection) prescribing information. Philadelphia: SmithKline Beecham Pharmaceuticals, Aug, 1995

  14. Zofran (ondansetron hydrochloride injection) prescribing information. Cerenex Pharmaceuticals, Division of Glaxo Wellcome, Aug, 1993

  15. Lee CR, Plosker GL, McTavish D. Tropisetron: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993; 46: 925–43

    Article  PubMed  CAS  Google Scholar 

  16. Miller RC, Galvan M, Gittos MW, et al. Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res 1993; 28: 87–93

    Article  CAS  Google Scholar 

  17. Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomized comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high-dose cisplatin chemotherapy. Eur J Cancer 1996; 32A(5): 807–13

    PubMed  CAS  Google Scholar 

  18. Galvan M, Claverie N, Hahne W. Pharmacology and metabolism of dolasetron mesilate. European Hospital Pharmacy 1996; 2 Suppl. 1: S12–4

    Google Scholar 

  19. Andrews PLR, Bhandari P, Davey PT, et al. Are all 5-HT3 receptor antagonists the same? Eur J Cancer 1992; 28A Suppl. 1: S2–6

    Article  PubMed  CAS  Google Scholar 

  20. Van Wijngaarden I, Tulp MThM, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharm Mol Pharmacol 1990; 188: 301–12

    Article  Google Scholar 

  21. Newberry NR, Watkins CJ, Sprosen TS, et al: BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors. Neuropharmacology 1993; 32: 729–35

    Article  PubMed  CAS  Google Scholar 

  22. Chevallier B, Bleiberg H, Fauser AA, et al. Dolasetron in the control of chemotherapy-induced nausea and vomiting. European Hospital Pharmacy 1996; 2 Suppl. 1: S38–42

    Google Scholar 

  23. Fauser AA, Duclos B, Chemaissani A, et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer 1996; 32A(5): 1523–9

    Article  PubMed  CAS  Google Scholar 

  24. Bertoli L, Yeilding A, Hankins J, et al. Antiemetic dose finding study of a specific 5-hydroxytryptamine (5-HT3) receptor antagonist (MDL 73, 147EF) in patients receiving high dose cisplatin chemotherapy [abstract]. Proc Am Soc Clin Oncol 1992; 11: 395

    Google Scholar 

  25. Yeilding AL, Bertoli L, Eisenberg PD, et al. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high dose cisplatin-containing chemotherapy. Am J Clin Oncol 1996; 19: 619–23

    Article  PubMed  CAS  Google Scholar 

  26. Hesketh P, Navari R, Grate T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996; 14: 2242–9

    PubMed  CAS  Google Scholar 

  27. Hesketh PJ, Gandara DR, Hesketh AM, et al. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 1996; 4: 141–6

    Article  PubMed  CAS  Google Scholar 

  28. Kris MG. Phase II trials of ondansetron with high-dose cisplatin. Semin Oncol 1992; 19(4) Suppl. 10: 23–7

    PubMed  CAS  Google Scholar 

  29. Cooke CE, Mehra IV. Oral ondansetron for preventing nausea and vomiting. Am J Hosp Pharm 1994; 51: 762–71

    PubMed  CAS  Google Scholar 

  30. Perez EA, Gandara DR. The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis. Semin Oncol 1994; 21 Suppl. 5: 15–21

    PubMed  CAS  Google Scholar 

  31. Bonneterre J, Hecquet B. Granisetron IV compared with ondansetron IV plus tablets in the prevention of nausea and vomiting induced by a moderately emetogenic chemotherapy regimen: a randomized cross-over study. Seventh European Conference of Clinical Oncology meeting; 1993 Nov: Jerusalem, Israel: 22–4

    Google Scholar 

  32. Jantunen IT, Muhonen TT, Kataja VV, et al. 5-HT5 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy — a randomized study. Eur J Cancer 1993; 29A: 1669–72

    Article  PubMed  CAS  Google Scholar 

  33. Perez EA, Lembersky B, Kaywin P, et al. Intravenous granisetron vs. ondansetron in the prevention of cyclophosphamidedoxorubicin-induced emesis in breast cancer patients: a double blind crossover study [abstract]. Proc Am Soc Clin Oncol 1996; 15: 543

    Google Scholar 

  34. Perez EA, Chawla SP, Kaywin P, et al. Efficacy and safety of oral granisetron vs. IV ondansetron in prevention of moderately emetogenic chemotherapy-induced nausea and vomiting [abstract]. Proc Am Soc Clin Oncol 1997; 16: 43a

    Google Scholar 

  35. Noble A, Bremer K, Dilly SG. A double-blind, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety, and patient preference. Eur J Cancer 1994; 30A: 1083–8

    Article  PubMed  CAS  Google Scholar 

  36. Ruff P, Paska W, Groedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin induced acute emesis: a multicentre double-blind, randomized, parallel-group study. Oncology 1994; 51: 113–8

    Article  PubMed  CAS  Google Scholar 

  37. Mantovani A, Maccio LL, Curreli L, et al. Comparison of the effectiveness of three 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by highly emetogenic chemotherapy (high-dose cisplatin) for the treatment of primary head and neck cancer [abstract]. Proc Am Soc Clin Oncol 1994; 13: 428

    Google Scholar 

  38. Martoni A, Angeleli B, Guaraldi M, et al. Granisetron (GRA) vs. ondansetron (OND) in the prevention of cis-platinum induced emesis: an open randomized cross-over study [abstract]. Proc Soc Am Clin Oncol 1994; 13: 431

    Google Scholar 

  39. Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatininduced emesis. J Clin Oncol 1995; 13: 1242–8

    PubMed  CAS  Google Scholar 

  40. Gralla RJ, Popovic W, Strupp J, et al. Can an oral antiemetic regimen be as effective as intravenous treatment against cisplatin: results of a 1054 patient randomized study of oral granisetron vs. IV ondansetron [abstract]. Proc Am Soc Clin Oncol 1997; 16: 52a

    Google Scholar 

  41. Williams PD, Cohen ML, Turk JA. Electrocardiographic effects of zatosetron and ondansetron, two 5-HT3 receptor antagonists, in anesthetized dogs. Drug Dev Res 1991; 24: 277–84

    Article  CAS  Google Scholar 

  42. Lifsey DS, Gralla RJ, Clark RA, et al. Electrocardiographic changes with serotonin antagonist antiemetic: rate of occurrence and clinical relevance [abstract]. Proc Am Soc Clin Oncol 1993; 12: 463

    Google Scholar 

  43. Watanabe H, Hasegawa A, Shinozaki T, et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995; 35: 278–82

    Article  PubMed  CAS  Google Scholar 

  44. Ballard HS, Bottino G, Bottino J. Ondansetron and chest pain [letter]. Lancet 1992; 340: 1107

    Article  PubMed  CAS  Google Scholar 

  45. Navari RM, Kaplan HG, Gralla RJ, et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994; 12: 2204–10

    PubMed  CAS  Google Scholar 

  46. Riviere A, Granisetron Study Group. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994; 69 (5): 967–71

    Article  PubMed  CAS  Google Scholar 

  47. Soukop M, Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Supp Care Cancer 1994; 2: 177–83

    Article  CAS  Google Scholar 

  48. Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two singledose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992; 10: 1969–75

    PubMed  CAS  Google Scholar 

  49. Seynaeve C, Schuller J, Buser K, et al. Comparison of the antiemetic efficacy of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis: a multicentre, double-blind, randomized, parallel group study. Br J Cancer 1992; 66(1): 192–7

    Article  PubMed  CAS  Google Scholar 

  50. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995; 6: 805–10

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Foundation and Mayo Clinic Jacksonville, Jacksonville, Florida, USA

    Edith A. Perez

Authors
  1. Edith A. Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perez, E.A. A Risk-Benefit Assessment of Serotonin 5-HT3 Receptor Antagonists in Antineoplastic Therapy-Induced Emesis. Drug-Safety 18, 43–56 (1998). https://doi.org/10.2165/00002018-199818010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199818010-00004

Keywords

Search

Navigation